Literature DB >> 29555570

Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.

Moon Hyung Choi1, Ga Eun Park2, Soon Nam Oh1, Michael Yong Park2, Sung Eun Rha2, Young Joon Lee1, Seung Eun Jung1, Joon-Il Choi3.   

Abstract

RATIONALE AND
OBJECTIVES: To evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) using multiphasic computed tomography.
MATERIALS AND METHODS: The institutional review board approved this retrospective study. We evaluated 97 patients who underwent TACE (60 conventional TACE [cTACE] and 37 drug-eluting bead TACE [DEB-TACE]) for HCC from 2010 to 2014. Four radiologists evaluated pairs of dynamic liver CTs scanned within 2 months before and after TACE based on mRECIST. Assessment of intra- or interobserver reproducibility for response categorization and sum of long diameter were evaluated using weighted kappa statistics (κ) and intraclass correlation coefficients, respectively. The relationship between concordance of target lesion selection and agreement of target lesion response was evaluated using Fisher exact test.
RESULTS: Intraobserver reproducibility for overall response was moderate to excellent (κ = 0.525-0.865). Interobserver reproducibility was improved on the second review compared to the first review and it was good in both treatment groups (κ = 0.627 for cTACE and 0.602 for DEB-TACE). Between the two treatment methods, intra- or interobserver reproducibility was better after cTACE than DEB-TACE. Intraclass correlation coefficients for sum of long diameter measurement showed excellent intra- or interobserver reproducibility. The concordance rate of target lesion selection was significantly higher for patients with radiologists' agreement for target lesion response than patients with disagreed response (P = .003).
CONCLUSIONS: The intra- and interobserver reproducibility of mRECIST in patients with HCC after TACE was moderate to excellent, and the reproducibility was slightly better after cTACE than DEB-TACE.
Copyright © 2018 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computed tomography; hepatocellular carcinoma; modified response evaluation criteria in solid tumors; reproducibility; transarterial chemoembolization

Mesh:

Year:  2018        PMID: 29555570     DOI: 10.1016/j.acra.2018.02.013

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  7 in total

1.  Predictors of response and survival in patients with unresectable hepatocellular carcinoma treated with nivolumab: real-world experience.

Authors:  Wei-Fan Hsu; Po-Heng Chuang; Cheng-Kuo Chen; Hung-Wei Wang; Ming-Hung Tsai; Wen-Pang Su; Hung-Yao Chen; Chi-Ying Yang; Chun-Che Lin; Guan-Tarn Huang; Jaw-Town Lin; Hsueh-Chou Lai; Cheng-Yuan Peng
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 2.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

3.  Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma.

Authors:  Ilaria Vicentin; Cristina Mosconi; Enrico Garanzini; Carlo Sposito; Matteo Serenari; Vincenzo Buscemi; Martina Verna; Carlo Spreafico; Rita Golfieri; Vincenzo Mazzaferro; Luciano De Carlis; Matteo Cescon; Giorgio Ercolani; Angelo Vanzulli; Alessandro Cucchetti
Journal:  Eur Radiol       Date:  2021-06-12       Impact factor: 5.315

4.  LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.

Authors:  Ali Pirasteh; E Aleks Sorra; Hector Marquez; Robert C Sibley; Julia R Fielding; Abhinav Vij; Nicole E Rich; Ana Arroyo; Adam C Yopp; Gaurav Khatri; Amit G Singal; Takeshi Yokoo
Journal:  Abdom Radiol (NY)       Date:  2021-03-23

5.  Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.

Authors:  Wei-Fan Hsu; Hung-Wei Wang; Cheng-Kuo Chen; Hsueh-Chou Lai; Po-Heng Chuang; Ming-Hung Tsai; Wen-Pang Su; Hung-Yao Chen; Chia-Sheng Chu; Jen-Wei Chou; Sheng-Hung Chen; Tsung-Yu Tsai; Wang-De Hsiao; Chun-Che Lin; Guan-Tarn Huang; Jaw-Town Lin; Cheng-Yuan Peng
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Authors:  Sandra Huicochea Castellanos; Andrew Pagano; Andrew J Plodkowski; Jeffrey Girshman; Matthew D Hellmann; Hira Rizvi; Jessica Flynn; Junting Zheng; Marinela Capanu; Darragh F Halpenny; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2021-09-04       Impact factor: 5.705

7.  The prognostic role of early tumor shrinkage in patients with hepatocellular carcinoma undergoing immunotherapy.

Authors:  Lukas Müller; Simon Johannes Gairing; Roman Kloeckner; Friedrich Foerster; Eva Maria Schleicher; Arndt Weinmann; Jens Mittler; Fabian Stoehr; Moritz Christian Halfmann; Christoph Düber; Peter Robert Galle; Felix Hahn
Journal:  Cancer Imaging       Date:  2022-09-24       Impact factor: 5.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.